Medicare Enrolled
Dr. Adam Reynolds, M.D.
Neurology · Boston, MA
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Reynolds from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Reynolds?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Reynolds
Dr. Adam Reynolds is a neurology specialist in Boston, MA, with 15 years of NPI registration. Based on federal Medicare data, Dr. Reynolds performed 11,010 Medicare services across 724 unique beneficiaries.
Between the years covered by Open Payments, Dr. Reynolds received a total of $8,532 from 42 pharmaceutical and/or device companies across 127 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in neurology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Reynolds is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 15 years in practice
▲ Top 5% volume in MA
$8,532 industry payments
Medicare Practice Summary
Medicare Utilization ↗11,010
Medicare services
Top 5% in MA for neurology
724
Unique beneficiaries
$10
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~734 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Botox injection, per unit An injection of onabotulinumtoxinA, a medication used to temporarily relax muscles or reduce gland activity. The dose is measured in units, with this code representing a single unit administered. |
10,181 | $5 | $15 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
143 | $78 | $271 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
137 | $102 | $413 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
135 | $52 | $182 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
88 | $49 | $175 |
| Electromyography of arm or leg muscles A test that measures the electrical activity in the muscles of the arm or leg using a needle electrode. It helps evaluate the health of muscles and the nerve cells that control them. |
61 | $72 | $230 |
| Limited needle EMG of arm or leg muscles A test that measures the electrical activity in specific muscles of the arm or leg using a needle electrode. This limited study evaluates muscle function in a targeted area. |
38 | $45 | $148 |
| Bilateral facial and neck nerve muscle paralysis injection Injection of a chemical agent to paralyze muscles in the face and neck on both sides. |
31 | $112 | $375 |
| Needle measurement of electrical activity in muscle with injection of chemical for paralysis of nerve muscle | 30 | $55 | $182 |
| Gadolinium MRI contrast injection Administration of a gadolinium-based contrast agent to enhance magnetic resonance imaging. The dose is measured per milliliter of the agent injected. |
27 | $1 | $26 |
| MRI scan of brain, without contrast A magnetic resonance imaging test of the brain that does not use contrast dye. This procedure creates detailed images of the brain's structure using magnetic fields and radio waves. |
23 | $136 | $575 |
| Nerve conduction studies, 7-8 tests A series of 7 to 8 nerve conduction tests to evaluate how well nerves are sending signals to muscles. |
23 | $131 | $495 |
| MRI of brain with and without contrast An MRI scan of the brain using contrast dye both before and after administration to provide detailed images of brain structures. |
22 | $239 | $1,200 |
| Chemical nerve block for neck muscles Injection of a chemical agent to paralyze specific muscles on the side of the neck, excluding the voice box. |
20 | $127 | $416 |
| Nerve conduction study, 3-4 tests A diagnostic test that measures how well nerves send electrical signals. It involves performing 3 to 4 separate nerve conduction studies to evaluate nerve function. |
20 | $76 | $314 |
| Nerve conduction studies, 5-6 tests A series of 5 to 6 tests that measure how well nerves send electrical signals. The procedure evaluates nerve function and helps identify damage or dysfunction. |
20 | $101 | $372 |
| MRI of upper spine without contrast An MRI scan of the upper spinal canal that does not use contrast dye. This imaging test uses magnetic fields and radio waves to create detailed pictures of the spine. |
11 | $139 | $558 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
0.8% high complexity
94.1% medium
5.1% routine
Industry Payment Transparency
Open Payments through 2024 ↗$8,532
Total received (2018-2024)
Avg $1,219/year across 7 years
Top 27% in MA for neurology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
42
Companies
127
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$4,707 (55.2%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$2,700 (31.6%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$1,125 (13.2%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$3,174
2023
$2,265
2022
$1,851
2021
$177
2020
$293
2019
$291
2018
$480
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Lundbeck LLC
$1,645
Medtronic, Inc.
$1,301
ABBVIE INC.
$46
Alexion Pharmaceuticals, Inc.
$35
Amgen Inc.
$33
Novartis Pharmaceuticals Corporation
$32
JAZZ PHARMACEUTICALS INC.
$29
UCB, Inc.
$20
CATALYST PHARMACEUTICALS, INC.
$17
Alnylam Pharmaceuticals Inc.
$16
Top 3 companies account for 94.3% of 2024 payments
All-time payments by company (2018-2024) ›
Medtronic, Inc.
$2,167
Lundbeck LLC
$1,678
ARGENX US, INC.
$1,125
Nevro Corp.
$1,016
Alexion Pharmaceuticals, Inc.
$356
Abbott Laboratories
$186
Novartis Pharmaceuticals Corporation
$152
Inspire Medical Systems, Inc.
$151
PORTOLA PHARMACEUTICALS, INC.
$143
ABBVIE INC.
$142
Boston Scientific Corporation
$126
SK Life Science, Inc.
$125
Horizon Therapeutics plc
$122
Genentech USA, Inc.
$108
Biogen, Inc.
$105
Amgen Inc.
$104
Allergan, Inc.
$93
UCB, Inc.
$79
Allergan Inc.
$55
Alnylam Pharmaceuticals Inc.
$52
Upsher-Smith Laboratories LLC
$48
Acorda Therapeutics, Inc
$38
Grifols USA, LLC
$35
JAZZ PHARMACEUTICALS INC.
$29
CSL Behring
$26
AbbVie Inc.
$23
Celgene Corporation
$22
Ultragenyx Pharmaceutical Inc.
$21
IMPEL PHARMACEUTICALS INC.
$20
Kyowa Kirin, Inc.
$18
Eisai Inc.
$17
CATALYST PHARMACEUTICALS, INC.
$17
Lilly USA, LLC
$16
PFIZER INC.
$15
Assertio Therapeutics, Inc.
$14
Strongbridge US INC.
$14
EMD Serono, Inc.
$14
Merz Pharmaceuticals, LLC
$14
Mallinckrodt LLC
$13
Sunovion Pharmaceuticals Inc.
$12
Teva Pharmaceuticals USA, Inc.
$11
Biohaven Pharmaceuticals, Inc.
$11
Top 3 companies account for 58.2% of all-time payments
Associated products mentioned in payments ›
ACTHAR · ADUHELM · AGAMREE · AIMOVIG · AJOVY · AMPYRA · AMVUTTRA · ANDEXXA · APTIOM · Aimovig · BOTOX · Briviact · CAMBIA · COMIRNATY · EMGALITY · EPIDIOLEX · Gamunex-C · Hizentra · INBRIJA · INSPIRE · INTELLIS ADAPTIVESTIM · INTERSTIM · KESIMPTA · KEVEYIS · Leqembi · Mavenclad · NAMZARIC · NOURIANZ · NURTEC ODT · OCREVUS · ONPATTRO · PROCLAIM · QUDEXY XR Topiramate Extended Release Capsules · QULIPTA · SOLIRIS · Senza · Soliris · TYSABRI · Trudhesa · UBRELVY · ULTOMIRIS · UPLIZNA · VANTA ADAPTIVESTIM · VUMERITY · VYEPTI · WATCHMAN · XCOPRI · Xeomin · ZEPOSIA · Zilbrysq
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (55%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
Neurologists within 10 mi
675
Per 100K population
86.3
County median income
$92,859
Nearest hospital
MASSACHUSETTS GENERAL HOSPITAL
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Reynolds is a mixed practice specialist, with above-average Medicare volume (top 5% in MA), with low-engagement industry engagement, with 15 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Reynolds experienced with botox injection, per unit?
Based on Medicare claims data, Dr. Reynolds performed 10,181 botox injection, per unit services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Reynolds receive payments from pharmaceutical companies?
Yes. Dr. Reynolds received a total of $8,532 from 42 companies across 127 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Reynolds's costs compare to other neurologists in Boston?
Dr. Reynolds's average Medicare payment per service is $10. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Reynolds) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Specialty guide
Understanding Neurology
Common procedures, typical costs, and what industry payments mean in neurology.
Same specialty & city
Neurologists in Boston
Browse neurologists in Boston ranked by procedure volume and transparency data.
Highest volume
Top Neurologists in MA
Neurologists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Neurologists in MA
Which MA neurologists receive the most from drug and device companies.
By company
Medtronic, Inc. Payments to Doctors
See all physicians who received payments from Medtronic, Inc.
By company
Lundbeck LLC Payments to Doctors
See all physicians who received payments from Lundbeck LLC.
By company
ARGENX US, INC. Payments to Doctors
See all physicians who received payments from ARGENX US, INC.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology